Pyxis Oncology (PYXS) Receivables - Other (2022 - 2023)
Pyxis Oncology's (PYXS) quarterly Receivables - Other came in at $21000.0 in Q4 2023, down 96.49% year-on-year from $598000.0 in Q4 2022, and down 96.49% on a QoQ basis from $598000.0 in Q4 2022.
Pyxis Oncology (PYXS) Receivables - Other (2022 - 2023) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of Receivables - Other data on file, last reported at $21000.0 in Q4 2023.
- On a quarterly basis, Receivables - Other fell 96.49% year-over-year to $21000.0 in Q4 2023; TTM through Dec 2023 was $21000.0, a 96.49% decrease from a year earlier, with the FY2023 full-year figure at $21000.0, down 96.49% from the prior year.
- Receivables - Other for Q4 2023 stood at $21000.0, down from $598000.0 in the prior quarter.
- Over the last five years, Receivables - Other for PYXS reached as high as $598000.0 in Q4 2022 and fell as low as $21000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2022 | 598,000.00 |
| Dec 31, 2022 | 598,000.00 |